Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products

Journal of Wound Care
Adrienne M GilliganAdam S Landsman

Abstract

Determine the cost-effectiveness of extracellular matrix (ECM) relative to human fibroblast-derived dermal substitute (HFDS) on diabetic foot ulcer (DFU) wound closure. Outcomes data were obtained from a 12-week, randomised, clinical trial of adults aged 18 years or older diagnosed with type 1 or type 2 diabetes with a DFU. Patients were treated with either ECM or HFDS treatment. A two-state Markov model (healed and unhealed) with a 1-week cycle length was developed using wound-closure rates from the trial to estimate the number of closed-wound weeks and the expected DFU cost per patient. Results were recorded over 12 weeks to estimate the number of closed-wound weeks per treatment and the average cost to achieve epithelialisation (primary outcome). The perspective of the analysis was that of the payer, specifically the Centers for Medicare and Medicaid Services. No cost discounting was performed because of the short duration of the study. The study consisted of 26 patients, with 13 in each group. In the ECM group, 10 wounds closed (77%), with an average closure time of 36 days; 11 wounds closed in the HFDS group (85%), with an average closure time of 41 days. There was no significant difference between these results (p=0.73). ...Continue Reading

References

Nov 1, 1977·The British Journal of Surgery·H M Adair
Jan 1, 1991·Annals of Surgery·K HaukipuroJ Risteli
Jul 1, 1989·The Journal of Surgical Research·S F BadylakL A Geddes
Jan 1, 1984·Journal of Cellular Biochemistry·F Grinnell
Apr 1, 1994·Archives of Dermatology·G S LazarusM C Robson
Oct 1, 1993·Medical Decision Making : an International Journal of the Society for Medical Decision Making·F A Sonnenberg, J R Beck
Feb 10, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·M E EdmondsM McColgan
Oct 20, 1998·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·K HehenbergerA Hansson
Mar 8, 1998·PharmacoEconomics·A Briggs, M Sculpher
May 18, 2000·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·K C OngenaeH Y Park
Oct 29, 2002·The Journal of Foot and Ankle Surgery : Official Publication of the American College of Foot and Ankle Surgeons·Jason R Hanft, Maria S Surprenant
May 27, 2003·Diabetes Care·David J MargolisJesse A Berlin
May 27, 2003·Diabetes Care·William A MarstonUNKNOWN Dermagraft Diabetic Foot Ulcer Study Group
Jun 9, 2005·Advances in Skin & Wound Care·Jeffrey A NiezgodaJason P Hodde
Feb 9, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·U PerssonJ Apelqvist
Jun 9, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·R Blakytny, E Jude
Jan 4, 2007·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·David L SteedLaurel Wiersma-Bryant
Feb 7, 2007·The Journal of Foot and Ankle Surgery : Official Publication of the American College of Foot and Ankle Surgeons·Robert G FrykbergUNKNOWN American College of Foot and Ankle Surgeons
Aug 18, 2010·Archives of Dermatology·Robert S KirsnerKatherine Freeman
Jun 1, 2012·Advances in Wound Care·Charles E HartJan Lessem

❮ Previous
Next ❯

Citations

Apr 12, 2016·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·T B Katrien SantemaDirk T Ubbink
Mar 12, 2017·Expert Review of Pharmacoeconomics & Outcomes Research·Ioannis PetrakisKostas Athanasakis
Feb 13, 2016·The Cochrane Database of Systematic Reviews·Trientje B SantemaDirk T Ubbink
Sep 29, 2018·The Journal of Dermatological Treatment·Christina DaiAmor Khachemoune
Feb 21, 2019·Experimental and Therapeutic Medicine·Juanzi ZhangZhijun Xue

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation

Software Mentioned

TreeAge

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.